Cellectis Q1 2026 Earnings Report

Cellectis EPS Results

• Actual EPS: -$0.18
• Consensus EPS: -$0.26
• Beat/Miss: Beat by +$0.08
• One Year Ago EPS: N/A

Cellectis Revenue Results

• Actual Revenue: $7.55 million
• Expected Revenue: $11.04 million
• Beat/Miss: Missed by -$3.49 million
• YoY Revenue Growth: N/A

Cellectis Announcement Details

• Quarter: Q1 2026
• Date: 5/11/2026
• Time: After Market Closes
• Conference Call Date: Monday, May 11, 2026
• Conference Call Time: 4:00PM ET

Cellectis (NASDAQ:CLLS) (NASDAQ: CLLS) is a clinical-stage biotechnology company focused on developing gene-edited, allogeneic T-cell therapies for cancer. The company uses its gene-editing technologies, including TALEN-based technology, to modify immune cells so they can be manufactured in advance and potentially administered to multiple patients rather than produced individually.

Cellectis’ product candidates are designed primarily as chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and other serious diseases. Its pipeline has included UCART programs targeting blood cancers, with research focused on improving the persistence, safety and activity of off-the-shelf engineered immune-cell products. The company advances its programs through internal research, clinical development and strategic collaborations.

Founded in 1999, Cellectis has operations and research activities in France and the United States, serving the global biopharmaceutical and oncology markets. The company has also pursued collaborations with larger pharmaceutical companies, including AstraZeneca, to support the development of gene-edited cell therapies. Cellectis is headquartered in Paris, France, and is led by co-founder André Choulika, who has served as chief executive officer.